Torrent Pharmaceuticals Limited (TORNTPHARM) - Net Assets

Latest as of March 2026: Rs175.85 Billion INR ≈ $1.90 Billion USD

Based on the latest financial reports, Torrent Pharmaceuticals Limited (TORNTPHARM) has net assets worth Rs175.85 Billion INR (≈ $1.90 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs443.12 Billion ≈ $4.79 Billion USD) and total liabilities (Rs267.27 Billion ≈ $2.89 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Torrent Pharmaceuticals Limited to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs175.85 Billion
% of Total Assets	39.68%
Annual Growth Rate	21.1%
5-Year Change	195.4%
10-Year Change	304.2%
Growth Volatility	26.48

Torrent Pharmaceuticals Limited - Net Assets Trend (2005–2026)

This chart illustrates how Torrent Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. See how many days can Torrent Pharmaceuticals Limited fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Torrent Pharmaceuticals Limited (2005–2026)

The table below shows the annual net assets of Torrent Pharmaceuticals Limited from 2005 to 2026. For live valuation and market cap data, see Torrent Pharmaceuticals Limited (TORNTPHARM) total market value.

Year	Net Assets	Change
2026-03-31	Rs175.85 Billion ≈ $1.90 Billion	+131.66%
2025-03-31	Rs75.91 Billion ≈ $820.94 Million	+10.72%
2024-03-31	Rs68.56 Billion ≈ $741.47 Million	+10.62%
2023-03-31	Rs61.98 Billion ≈ $670.29 Million	+4.12%
2022-03-31	Rs59.53 Billion ≈ $643.79 Million	+1.98%
2021-03-31	Rs58.37 Billion ≈ $631.27 Million	+21.02%
2020-03-31	Rs48.23 Billion ≈ $521.61 Million	+2.09%
2019-03-31	Rs47.24 Billion ≈ $510.92 Million	+2.20%
2018-03-31	Rs46.23 Billion ≈ $499.93 Million	+6.25%
2017-03-31	Rs43.51 Billion ≈ $470.50 Million	+28.36%
2016-03-31	Rs33.89 Billion ≈ $366.56 Million	+36.07%
2015-03-31	Rs24.91 Billion ≈ $269.39 Million	+30.91%
2014-03-31	Rs19.03 Billion ≈ $205.78 Million	+33.79%
2013-03-31	Rs14.22 Billion ≈ $153.82 Million	+18.79%
2012-03-31	Rs11.97 Billion ≈ $129.49 Million	+16.92%
2011-03-31	Rs10.24 Billion ≈ $110.74 Million	+23.23%
2010-03-31	Rs8.31 Billion ≈ $89.87 Million	+27.67%
2009-03-31	Rs6.51 Billion ≈ $70.39 Million	+27.74%
2008-03-31	Rs5.10 Billion ≈ $55.11 Million	+24.21%
2007-03-31	Rs4.10 Billion ≈ $44.37 Million	+17.94%
2006-03-31	Rs3.48 Billion ≈ $37.62 Million	+10.24%
2005-03-31	Rs3.16 Billion ≈ $34.12 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Torrent Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs1.69 Billion	2.01%
Other Components	Rs82.20 Billion	97.99%
Total Equity	Rs83.89 Billion	100.00%

Torrent Pharmaceuticals Limited Competitors by Market Cap

The table below lists competitors of Torrent Pharmaceuticals Limited ranked by their market capitalization.

Company	Market Cap
Inner Mongolia BaoTou Steel Union Co Ltd SHG:600010	$16.37 Billion
Woori Financial Group Inc KO:316140	$16.37 Billion
Franklin Resources Inc NYSE:BEN	$16.39 Billion
nVent Electric PLC NYSE:NVT	$16.41 Billion
Alamos Gold Inc TO:AGI	$16.34 Billion
Nordson Corporation NASDAQ:NDSN	$16.32 Billion
Emera Inc. TO:EMA	$16.29 Billion
Beiersdorf Aktiengesellschaft F:BEIA	$16.28 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Torrent Pharmaceuticals Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 75,910,000,000 to 83,890,000,000, a change of 7,980,000,000 (10.5%).
Net income of 21,630,000,000 contributed positively to equity growth.
Dividend payments of 12,890,000,000 reduced retained earnings.
Other comprehensive income decreased equity by 26,749,100,000.
Other factors increased equity by 25,989,100,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs21.63 Billion	+25.78%
Dividends Paid	Rs12.89 Billion	-15.37%
Other Comprehensive Income	Rs-26.75 Billion	-31.89%
Other Changes	Rs25.99 Billion	+30.98%
Total Change	Rs-	10.51%

Book Value vs Market Value Analysis

This analysis compares Torrent Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 18.02x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 479.09x to 18.02x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs9.32	Rs4466.70	x
2006-03-31	Rs10.28	Rs4466.70	x
2007-03-31	Rs12.12	Rs4466.70	x
2008-03-31	Rs15.06	Rs4466.70	x
2009-03-31	Rs19.23	Rs4466.70	x
2010-03-31	Rs24.55	Rs4466.70	x
2011-03-31	Rs30.21	Rs4466.70	x
2012-03-31	Rs35.27	Rs4466.70	x
2013-03-31	Rs42.01	Rs4466.70	x
2014-03-31	Rs56.21	Rs4466.70	x
2015-03-31	Rs73.59	Rs4466.70	x
2016-03-31	Rs100.14	Rs4466.70	x
2017-03-31	Rs128.53	Rs4466.70	x
2018-03-31	Rs136.57	Rs4466.70	x
2019-03-31	Rs139.59	Rs4466.70	x
2020-03-31	Rs142.51	Rs4466.70	x
2021-03-31	Rs172.47	Rs4466.70	x
2022-03-31	Rs175.89	Rs4466.70	x
2023-03-31	Rs183.13	Rs4466.70	x
2024-03-31	Rs202.58	Rs4466.70	x
2025-03-31	Rs224.31	Rs4466.70	x
2026-03-31	Rs247.91	Rs4466.70	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Torrent Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 25.78%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 15.47%
• Asset Turnover: 0.32x
• Equity Multiplier: 5.28x
Recent ROE (25.78%) is above the historical average (24.03%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	15.45%	8.90%	0.77x	2.25x	Rs172.08 Million
2006	14.62%	5.26%	1.03x	2.71x	Rs160.79 Million
2007	22.79%	7.20%	1.24x	2.55x	Rs524.88 Million
2008	26.43%	9.94%	1.07x	2.48x	Rs837.21 Million
2009	28.33%	11.31%	0.98x	2.56x	Rs1.19 Billion
2010	27.82%	12.61%	0.93x	2.36x	Rs1.48 Billion
2011	26.42%	12.78%	0.83x	2.49x	Rs1.68 Billion
2012	23.79%	10.95%	0.84x	2.57x	Rs1.65 Billion
2013	30.43%	14.20%	0.81x	2.66x	Rs2.91 Billion
2014	34.90%	16.46%	0.80x	2.66x	Rs4.74 Billion
2015	30.15%	16.40%	0.58x	3.18x	Rs5.02 Billion
2016	51.14%	26.59%	0.72x	2.66x	Rs13.94 Billion
2017	21.46%	16.46%	0.56x	2.33x	Rs4.99 Billion
2018	14.67%	11.64%	0.41x	3.08x	Rs2.16 Billion
2019	9.23%	5.85%	0.53x	2.99x	Rs-361.55 Million
2020	21.25%	13.17%	0.55x	2.91x	Rs5.42 Billion
2021	21.45%	15.87%	0.56x	2.41x	Rs6.68 Billion
2022	13.06%	9.23%	0.64x	2.20x	Rs1.82 Billion
2023	20.09%	13.16%	0.63x	2.42x	Rs6.25 Billion
2024	24.16%	15.68%	0.70x	2.20x	Rs9.71 Billion
2025	25.18%	16.89%	0.75x	1.97x	Rs11.52 Billion
2026	25.78%	15.47%	0.32x	5.28x	Rs13.24 Billion

Industry Comparison

This section compares Torrent Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $17,320,289,591
Average return on equity (ROE) among peers: 16.12%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Torrent Pharmaceuticals Limited (TORNTPHARM)	Rs175.85 Billion	15.45%	1.52x	$16.35 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$1.33 Billion	3.53%	1.28x	$24.20 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.76 Billion	12.24%	2.47x	$366.49 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.27 Million	-2.03%	0.10x	$626.77 Million
Abbott India Limited (ABBOTINDIA)	$8.33 Billion	20.02%	0.37x	$6.00 Billion
Ajanta Pharma Limited (AJANTPHARM)	$2.98 Billion	25.93%	1.18x	$4.16 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$30.64 Billion	11.04%	0.34x	$988.23 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.92 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$183.78 Million	32.19%	1.01x	$169.18 Million
Alembic Pharmaceuticals Limited (APLLTD)	$16.01 Billion	44.99%	0.54x	$1.59 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.69 Billion

About Torrent Pharmaceuticals Limited

NSE:TORNTPHARM India Drug Manufacturers - Specialty & Generic

Market Cap

$16.35 Billion

Rs1.51 Trillion INR

Market Cap Rank

#1541 Global

#49 in India

Share Price

Rs4466.70

Change (1 day)

-0.83%

52-Week Range

Rs3164.00 - Rs4572.60

All Time High

Rs4572.60